



absorbed by clothes fibers, and the blue fluorescence of the benzoxazole makes clothes appear “whiter than white.”



4,4'-bis(benzoxazol-2-yl)stilbene

Tilmaxcoxib is a COX-2 inhibiting, oxazole-containing, nonsteroidal anti-inflammatory agent,<sup>7</sup> and valdecoxib is an isoxazole NSAID.<sup>8</sup> Formation of the sodium salt of an *N*-acylated derivative of valdecoxib affords parecoxib,<sup>9</sup> a water-soluble valdecoxib prodrug amenable to injectable formulations. Valdecoxib was withdrawn from the US market in 2005 due to concern of increased risk of heart attack or stroke. While parecoxib is approved for use in the EU, the US FDA issued a letter of non-approval for the drug, also in 2005. While no documentation for the non-approval was made public, proximity to the 2004 withdrawal of rofecoxib (Vioxx) cannot be overlooked.



tilmaxcoxib

